
|Articles|June 28, 2016
Norgine Divests MENA Operations and Products to Switzerland's Acino
June 28, 2016
Advertisement
Norgine (Amsterdam, The Netherlands) has completed the divestment of its MENA (Middle East and Africa) operations and rights for a number of its products in MENA to Acino (Aesch, Switzerland).
Kalle Känd, CEO of Acino said: “The products [MOVICOL, MOVIPREP, KLEAN-PREP and NORMACOL] are complementary to our existing portfolio in these markets and will considerably strengthen our offer in one of our core therapeutic areas – gastroenterology.”
The transaction includes the transfer of Norgine’s employees and entities in Egypt and employees in Tunisia. Norgine will continue to manufacture its own products for Acino.
Financial terms were not disclosed.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Market
2
Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion
3
Catalent Announces Expanded Partnership with Nanoscope Therapeutics
4
Reshoring Pharma and Biotech Manufacturing Ahead of This Summer’s Tariff Deadlines: Q&A with Ryan Last
5




